Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients

By | November 16, 2021
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds.